{"id":"venetoclax-400","safety":{"commonSideEffects":[{"rate":"50-70%","effect":"Neutropenia"},{"rate":"30-50%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Infections"},{"rate":"10-20%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting BCL-2, venetoclax promotes apoptosis in cancer cells, leading to cell death. This mechanism is particularly effective in treating certain types of leukemia, such as chronic lymphocytic leukemia (CLL).","oneSentence":"Venetoclax is a small molecule inhibitor of the BCL-2 protein, which is involved in apoptosis regulation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:28.228Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia (CLL)"},{"name":"Acute myeloid leukemia (AML)"}]},"trialDetails":[{"nctId":"NCT07407140","phase":"PHASE3","title":"VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-30","conditions":"AML, Adult","enrollment":300},{"nctId":"NCT07490288","phase":"NA","title":"Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"AML","enrollment":30},{"nctId":"NCT03534323","phase":"PHASE1, PHASE2","title":"Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-07-12","conditions":"Chronic Lymphocytic Leukemia, Richter Syndrome","enrollment":55},{"nctId":"NCT07486479","phase":"PHASE3","title":"Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-03-10","conditions":"Acute Myeloid Leukemia (AML)","enrollment":204},{"nctId":"NCT07486726","phase":"PHASE1, PHASE2","title":"Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2026-03-15","conditions":"Acute Myeloid Leukemia (AML), Relapse Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia (AML)","enrollment":112},{"nctId":"NCT06928376","phase":"PHASE2","title":"A Multicenter RCT of \"3+7\" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-04-18","conditions":"Acute Myeloid Leukemia, First Line Therapy","enrollment":160},{"nctId":"NCT04278768","phase":"PHASE1, PHASE2","title":"Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)","status":"SUSPENDED","sponsor":"Curis, Inc.","startDate":"2020-07-06","conditions":"Acute Myelogenous Leukemia, Myelodysplastic Syndrome","enrollment":366},{"nctId":"NCT05376111","phase":"PHASE2","title":"Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-04-01","conditions":"T-cell Acute Lymphoblastic Leukemia, Recruiting","enrollment":28},{"nctId":"NCT07478991","phase":"PHASE3","title":"Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)","status":"NOT_YET_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2026-03","conditions":"Acute Myeloid Leukemia, Adult","enrollment":376},{"nctId":"NCT07396480","phase":"PHASE3","title":"Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2026-03-01","conditions":"Venentoclax, Myeloid Malignancies, Conditioning","enrollment":186},{"nctId":"NCT05478512","phase":"PHASE2","title":"Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2023-07-21","conditions":"High Risk CLL, Chronic Lymphocytic Leukemia","enrollment":78},{"nctId":"NCT04926285","phase":"PHASE1","title":"Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2022-06-21","conditions":"Relapsed or Refractory Hematologic Malignancies","enrollment":6},{"nctId":"NCT04227847","phase":"PHASE1","title":"A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies","status":"RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2020-08-07","conditions":"Myelodysplastic Syndrome, Acute Myeloid Leukemia","enrollment":178},{"nctId":"NCT03523975","phase":"PHASE1, PHASE2","title":"Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2018-12-24","conditions":"Mantle Cell Lymphoma","enrollment":28},{"nctId":"NCT05947851","phase":"PHASE3","title":"A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-08-08","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma","enrollment":735},{"nctId":"NCT07469046","phase":"PHASE3","title":"VAH vs VA in Newly Diagnosed Elderly AML","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-03-01","conditions":"Acute Myeloid Leukemia (AML), Elderly Patients (60-75 Years)","enrollment":308},{"nctId":"NCT05963074","phase":"PHASE2","title":"A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-05-30","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma","enrollment":320},{"nctId":"NCT05782127","phase":"PHASE1, PHASE2","title":"Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2023-12-06","conditions":"Untreated Myelodysplastic Syndrome","enrollment":36},{"nctId":"NCT05226455","phase":"PHASE1, PHASE2","title":"Venetoclax in Patients With MDS or AML in Relapse After AHSCT","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2022-11-23","conditions":"MDS, AML","enrollment":55},{"nctId":"NCT03462719","phase":"PHASE3","title":"A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-17","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":211},{"nctId":"NCT06456463","phase":"PHASE2","title":"A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy","status":"RECRUITING","sponsor":"Stemline Therapeutics, Inc.","startDate":"2025-01-14","conditions":"Acute Myeloid Leukemia","enrollment":83},{"nctId":"NCT03336333","phase":"PHASE3","title":"A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2017-10-31","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":590},{"nctId":"NCT07454226","phase":"NA","title":"ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Ph-Like, Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT05768711","phase":"PHASE2","title":"Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2023-10-04","conditions":"Chronic Myeloid Leukemia","enrollment":44},{"nctId":"NCT07451912","phase":"PHASE1, PHASE2","title":"Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-09-15","conditions":"Acute Myeloid Leukemia (AML), CEBPA Mutation, Unfit, New-diagnosis AML","enrollment":29},{"nctId":"NCT07294677","phase":"PHASE1, PHASE2","title":"CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2026-03-17","conditions":"Leukemia, Lymphoma","enrollment":104},{"nctId":"NCT07044544","phase":"PHASE1","title":"Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-07-17","conditions":"Myeloid Malignancy, Hematologic Malignancy, Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT07283094","phase":"PHASE1","title":"FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-02-03","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":33},{"nctId":"NCT04285567","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-05-28","conditions":"Chronic Lymphocytic Leukemia (CLL)","enrollment":166},{"nctId":"NCT07132684","phase":"PHASE3","title":"Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-08-31","conditions":"AML, Adult","enrollment":240},{"nctId":"NCT04263181","phase":"","title":"AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2020-01-29","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":80},{"nctId":"NCT05650723","phase":"PHASE2","title":"Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2023-05-08","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":50},{"nctId":"NCT06524375","phase":"PHASE2","title":"A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2024-08-09","conditions":"Chronic Lymphocytic Leukemia","enrollment":118},{"nctId":"NCT03609593","phase":"PHASE2","title":"Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Nicole Lamanna","startDate":"2018-11-12","conditions":"Chronic Lymphocytic Leukemia","enrollment":42},{"nctId":"NCT06773208","phase":"PHASE2","title":"A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-01-07","conditions":"Acute Myeloid Leukemia (AML)","enrollment":30},{"nctId":"NCT07425808","phase":"PHASE2, PHASE3","title":"FLT3-ITD Targeted Therapy in Fit AML Patients","status":"NOT_YET_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2026-12-01","conditions":"AML (Acute Myeloid Leukemia)","enrollment":230},{"nctId":"NCT07425782","phase":"PHASE2","title":"Venetoclax Combined With Azacitidine for Consolidation Therapy in AML","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-02-01","conditions":"Acute Myeloid Leukemia, Consolidation Therapy, Venentoclax","enrollment":216},{"nctId":"NCT05530421","phase":"PHASE2","title":"Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"University of Miami","startDate":"2023-03-26","conditions":"Relapsed and Refractory Multiple Myeloma","enrollment":33},{"nctId":"NCT07423104","phase":"PHASE2","title":"A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"University of Rochester","startDate":"2026-08-15","conditions":"Acute Myeloid Leukemia (AML)","enrollment":24},{"nctId":"NCT03580928","phase":"PHASE2","title":"Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-08-07","conditions":"Chronic Lymphocytic Leukemia (CLL)","enrollment":72},{"nctId":"NCT05053659","phase":"PHASE1","title":"Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Paolo Caimi, MD","startDate":"2022-06-20","conditions":"Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma","enrollment":23},{"nctId":"NCT06558604","phase":"PHASE2","title":"Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma","status":"RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2025-02-21","conditions":"Lymphoma, Mantle-Cell","enrollment":100},{"nctId":"NCT07172204","phase":"PHASE2","title":"Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-09-16","conditions":"Intensive Chemotherapy Unfit, Newly Diagnosed Acute Myeloid Leukemia (AML), Age ≥60","enrollment":25},{"nctId":"NCT07259707","phase":"PHASE2","title":"Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2026-01-25","conditions":"Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication Positive, Intermediate Risk Acute Myeloid Leukemia","enrollment":25},{"nctId":"NCT04161248","phase":"EARLY_PHASE1","title":"Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2020-09-02","conditions":"Lymphoma, B-Cell","enrollment":18},{"nctId":"NCT05442216","phase":"PHASE2","title":"Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents","status":"RECRUITING","sponsor":"Joshua Zeidner","startDate":"2024-05-01","conditions":"Acute Myeloid Leukemia","enrollment":53},{"nctId":"NCT03926624","phase":"PHASE3","title":"Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage","status":"TERMINATED","sponsor":"Delta-Fly Pharma, Inc.","startDate":"2019-11-22","conditions":"Leukemia, Myeloid, Acute","enrollment":167},{"nctId":"NCT06068621","phase":"PHASE2","title":"Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2023-03-01","conditions":"Acute Myeloid Leukemia","enrollment":200},{"nctId":"NCT05287568","phase":"PHASE1","title":"CC-486 and Venetoclax for Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2022-12-19","conditions":"AML","enrollment":35},{"nctId":"NCT05317403","phase":"PHASE1","title":"Venetoclax to Augment Epigenetic Modification and Chemotherapy","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-03-31","conditions":"Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory","enrollment":40},{"nctId":"NCT05597306","phase":"PHASE1","title":"Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Terrence J Bradley, MD","startDate":"2022-11-19","conditions":"Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse","enrollment":18},{"nctId":"NCT05201066","phase":"PHASE2","title":"Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-02-13","conditions":"Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic","enrollment":33},{"nctId":"NCT04523428","phase":"PHASE2","title":"REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)","status":"RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2020-12-23","conditions":"CLL/SLL","enrollment":60},{"nctId":"NCT05184842","phase":"PHASE2","title":"Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2022-03-23","conditions":"Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia","enrollment":91},{"nctId":"NCT03708003","phase":"PHASE2","title":"Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL","status":"TERMINATED","sponsor":"Swiss Cancer Institute","startDate":"2019-03-11","conditions":"Relapsed/Refractory Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Leukemia","enrollment":30},{"nctId":"NCT05657639","phase":"PHASE2","title":"CAV Regimen for R/R AML","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-10-01","conditions":"Acute Myeloid Leukemia","enrollment":68},{"nctId":"NCT05657652","phase":"NA","title":"CAV Regimen for R/R Ph- B-ALL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-10-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":36},{"nctId":"NCT03467867","phase":"PHASE2","title":"A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Georgetown University","startDate":"2018-04-26","conditions":"Chronic Lymphocytic Leukemia","enrollment":25},{"nctId":"NCT05074355","phase":"PHASE2","title":"Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-11-08","conditions":"Myeloproliferative Neoplasm","enrollment":40},{"nctId":"NCT03013998","phase":"PHASE1, PHASE2","title":"Study of Biomarker-Based Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Beat AML, LLC","startDate":"2016-11","conditions":"Previously Untreated Relapsed Refractory Acute Myeloid Leukemia","enrollment":3000},{"nctId":"NCT05901974","phase":"PHASE2","title":"Venetoclax Combined With Azactidine in the Treatment of ALAL","status":"RECRUITING","sponsor":"Sheng-Li Xue, MD","startDate":"2023-07-01","conditions":"Acute Leukemia of Ambiguous Lineage","enrollment":23},{"nctId":"NCT04657081","phase":"PHASE1, PHASE2","title":"Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2021-02-09","conditions":"Acute Myeloid Leukemia","enrollment":101},{"nctId":"NCT03567876","phase":"PHASE2","title":"Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2018-09-03","conditions":"Lymphoma, Mantle-Cell","enrollment":141},{"nctId":"NCT04010968","phase":"PHASE2","title":"Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"2019-09-27","conditions":"Intermediate Risk Chronic Lymphocytic Leukemia, Fit Patients, Risk-Adapted and MRD-Driven Strategy","enrollment":120},{"nctId":"NCT03766763","phase":"PHASE2","title":"Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A","status":"ACTIVE_NOT_RECRUITING","sponsor":"French Innovative Leukemia Organisation","startDate":"2019-05-22","conditions":"Chronic Lymphoid Leukemia","enrollment":82},{"nctId":"NCT07238686","phase":"PHASE2","title":"Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS","status":"RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2025-06-20","conditions":"Myelodysplastic Syndromes","enrollment":40},{"nctId":"NCT05566054","phase":"PHASE2","title":"Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-03-01","conditions":"Acute Monocytic Leukemia, Newly Diagnosed","enrollment":92},{"nctId":"NCT05986240","phase":"PHASE1","title":"Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2024-05-08","conditions":"AML/MDS, Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":38},{"nctId":"NCT04937166","phase":"PHASE1","title":"A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies","status":"TERMINATED","sponsor":"Kahr Medical","startDate":"2022-01-13","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia","enrollment":25},{"nctId":"NCT02242942","phase":"PHASE3","title":"Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-12-31","conditions":"Lymphocytic Leukemia, Chronic","enrollment":445},{"nctId":"NCT04266795","phase":"PHASE2","title":"A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy","status":"COMPLETED","sponsor":"Takeda","startDate":"2020-10-13","conditions":"Acute Myeloid Leukemia (AML)","enrollment":164},{"nctId":"NCT04447768","phase":"PHASE2","title":"The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-12-03","conditions":"Chronic Lymphocytic Leukemia (CLL)","enrollment":100},{"nctId":"NCT07214064","phase":"PHASE2","title":"Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2026-01","conditions":"AML (Acute Myeloid Leukemia), MDS/AML, MDS (Myelodysplastic Syndrome)","enrollment":27},{"nctId":"NCT04812548","phase":"PHASE2","title":"A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-05-31","conditions":"Myelodysplastic Syndrome (MDS)","enrollment":20},{"nctId":"NCT04607772","phase":"PHASE1, PHASE2","title":"Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)","status":"WITHDRAWN","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-11-18","conditions":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","enrollment":""},{"nctId":"NCT05471700","phase":"NA","title":"Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients","status":"COMPLETED","sponsor":"Zhujiang Hospital","startDate":"2022-09-01","conditions":"Leukemia, Myeloid, Acute","enrollment":40},{"nctId":"NCT07183878","phase":"NA","title":"Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-08-20","conditions":"Acute Myeloid Leukemia, High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":138},{"nctId":"NCT06668558","phase":"PHASE2","title":"Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias","startDate":"2024-12-16","conditions":"Acute Myeloid Leukemia","enrollment":29},{"nctId":"NCT06918834","phase":"PHASE2","title":"Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-07-24","conditions":"Myelodysplastic Syndromes","enrollment":236},{"nctId":"NCT06384261","phase":"PHASE2","title":"A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy","status":"RECRUITING","sponsor":"OncoVerity, Inc.","startDate":"2024-07-22","conditions":"Leukemia, Myeloid, Acute","enrollment":120},{"nctId":"NCT06429098","phase":"PHASE2","title":"Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-01-01","conditions":"Acute Myeloid Leukemia","enrollment":40},{"nctId":"NCT06382168","phase":"PHASE1, PHASE2","title":"DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Delta-Fly Pharma, Inc.","startDate":"2024-06-12","conditions":"Leukemia, Myeloid, Acute","enrollment":39},{"nctId":"NCT06129734","phase":"PHASE1, PHASE2","title":"Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant","status":"RECRUITING","sponsor":"Benjamin Tomlinson","startDate":"2025-07-28","conditions":"Myeloid Malignancy, Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT02993523","phase":"PHASE3","title":"A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2017-02-02","conditions":"Acute Myeloid Leukemia (AML)","enrollment":443},{"nctId":"NCT07075016","phase":"PHASE3","title":"Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy","status":"RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2025-08-05","conditions":"Acute Myeloid Leukemia","enrollment":227},{"nctId":"NCT05197192","phase":"PHASE3","title":"A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL","status":"RECRUITING","sponsor":"German CLL Study Group","startDate":"2022-04-19","conditions":"Chronic Lymphocytic Leukemia","enrollment":202},{"nctId":"NCT04086264","phase":"PHASE1, PHASE2","title":"IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2019-11-06","conditions":"Acute Myeloid Leukemia","enrollment":218},{"nctId":"NCT06357182","phase":"PHASE1","title":"Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2024-08-22","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome/Acute Myeloid Leukemia","enrollment":24},{"nctId":"NCT07117422","phase":"NA","title":"Venetoclax-Decitabine in Untreated Elderly/Unfit AML","status":"RECRUITING","sponsor":"The Second Hospital of Hebei Medical University","startDate":"2025-01-17","conditions":"AML, Adult","enrollment":39},{"nctId":"NCT03834688","phase":"PHASE2","title":"Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age","status":"COMPLETED","sponsor":"PrECOG, LLC.","startDate":"2020-01-13","conditions":"Mantle Cell Lymphoma","enrollment":33},{"nctId":"NCT07047183","phase":"PHASE2","title":"Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes","status":"RECRUITING","sponsor":"Yehui Tan","startDate":"2025-07-01","conditions":"Myelodysplastic Neoplasms, Transplantation","enrollment":46},{"nctId":"NCT07108530","phase":"PHASE2","title":"Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-06","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT02899052","phase":"PHASE2","title":"Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2017-01-19","conditions":"Multiple Myeloma","enrollment":120},{"nctId":"NCT06386302","phase":"NA","title":"Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-08-05","conditions":"AML, Acute Myeloid Leukemia","enrollment":184},{"nctId":"NCT07078591","phase":"PHASE2","title":"Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML","status":"RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2025-06-20","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT02558816","phase":"PHASE1, PHASE2","title":"A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2015-10-14","conditions":"Mantle Cell Lymphoma","enrollment":48},{"nctId":"NCT07082452","phase":"PHASE3","title":"A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction","status":"NOT_YET_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09","conditions":"Leukemia, B-Cell, Chronic, Leukemia","enrollment":262},{"nctId":"NCT03112174","phase":"PHASE3","title":"Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2017-06-19","conditions":"Mantle-Cell Lymphoma","enrollment":366},{"nctId":"NCT05662956","phase":"PHASE2","title":"A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients","status":"COMPLETED","sponsor":"Hematology department of the 920th hospital","startDate":"2022-12-01","conditions":"Acute Myeloid Leukemia","enrollment":114},{"nctId":"NCT06810778","phase":"PHASE1, PHASE2","title":"Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2025-05-02","conditions":"T-cell-prolymphocytic Leukemia, Cutaneous T-Cell Lymphoma Refractory","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":43,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Venetoclax 400","genericName":"Venetoclax 400","companyName":"Stichting Hemato-Oncologie voor Volwassenen Nederland","companyId":"stichting-hemato-oncologie-voor-volwassenen-nederland","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Venetoclax is a small molecule used to treat various conditions, including Acute Myeloid Leukemia (AML), Acute Monocytic Leukemia, AL Amyloidosis, and Light Chain (AL) Amyloidosis. It is typically administered in combination with other treatments, such as Decitabine, or as a standalone intervention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}